The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Risk of secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality.
 
Matthew Parsons
No Relationships to Disclose
 
Jonathan Chipman
No Relationships to Disclose
 
Calvin Rock
No Relationships to Disclose
 
Deborah Marie Stephens
Honoraria - Genentech
Consulting or Advisory Role - Adaptive Biotechnologies; BeiGene; Epizyme; Innate Pharma; Karyopharm Therapeutics; Pharmacyclics/Janssen; TG Therapeutics
Research Funding - Acerta Pharma; ArQule; Gilead Sciences; Juno Therapeutics; Karyopharm Therapeutics; MingSight; Verastem
 
Harsh Shah
No Relationships to Disclose
 
Boyu Hu
Research Funding - Celgene; crispr therapeutics; miRagen; Roche/Genentech
 
Randa Tao
Consulting or Advisory Role - QED Therapeutics
Travel, Accommodations, Expenses - QED Therapeutics
 
Jonathan David Tward
Consulting or Advisory Role - Bayer; Bayer; Blue Earth Diagnostics; Boston Scientific; Janssen Scientific Affairs; Merck; Myriad Genetics
Research Funding - Bayer (Inst); Myriad Genetics (Inst)
Expert Testimony - Expert Consulting Services
 
David K. Gaffney
Consulting or Advisory Role - Merck
Research Funding - Elekta